Morgan Stanley Incannex Healthcare LTD Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.0 - $3.61 $0 - $8,079	2,238 Added 447.6%	2,738 $6,000
Q3 2022 Nov 14, 2022	SELL	$3.44 - $5.57 $2,064 - $3,342	-600 Reduced 54.55%	500 $2,000
Q2 2022 Oct 27, 2022	SELL	$3.86 - $9.14 $72,954 - $172,746	-18,900 Reduced 94.5%	1,100 $4,000
Q2 2022 Aug 15, 2022	SELL	$3.86 - $9.14 $72,954 - $172,746	-18,900 Reduced 94.5%	1,100 $4,000
Q1 2022 Oct 27, 2022	BUY	$9.16 - $35.5 $173,124 - $670,950	18,900 Added 1718.18%	20,000 $183,000
Q1 2022 May 13, 2022	BUY	$9.16 - $35.5 $183,200 - $710,000	20,000 New	20,000 $183,000

Ticker IXHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 51,693,400
Market Cap $151M
Description
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.